https://www.selleckchem.com/pr....oducts/pf-06882961.h
ICI-arm was associated with a slight increase of ≥ G3 AEs (relative risk 1.07). The results in multiple myeloma patients are controversial in favor of ICIs combinations. Adding ICIs to SOC benefits a greater number of patients, prolonging survival with no early detrimental effect. The toxicity profile is safe, with a mild increase of high-grade manageable AEs.With the iPad-mediated cognitive assessment gaining popularity with school districts and the need for alternative modes for training and instruction during this COVID-19 pandem
Like
Comment
Share
